Cover Image
市場調查報告書

市場預測:2016-2026年多發性骨髓瘤 (MM) 的主要18個國家

Multiple Myeloma Forecast in 18 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 357765
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
市場預測:2016-2026年多發性骨髓瘤 (MM) 的主要18個國家 Multiple Myeloma Forecast in 18 Major Markets 2016-2026
出版日期: 2016年05月12日 內容資訊: 英文 68 Pages
簡介

本報告提供全球主要18個國家市場上多發性骨髓瘤 (MM) 的患病情形調查,患病數的變化與預測,性別、症狀等各分類的明細,疾病概要,危險因素,疾病診斷與預後,主要的症狀和並存症等彙整資料。

調查對象國家

  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 愛爾蘭
  • 巴西
  • 日本
  • 印度
  • 沙烏地阿拉伯
  • 南非
  • 加拿大
  • 墨西哥
  • 土耳其
  • 阿根廷
  • 俄羅斯
  • 澳洲

目錄

  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 地區/民族的差異
  • 疾病預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 定量化患者數的手法
  • 多發性骨髓瘤的患病人數
  • 多發性骨髓瘤的階段
  • 多發性骨髓瘤患者的特徵
    • 組織病理學的分類
    • 骨病變的重症度
    • 免疫球蛋白/單株抗體蛋白的類型
  • 多發性骨髓瘤的相關症狀
  • 簡稱
  • 相關出版物
  • 線上資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: MMYE0010416

Multiple Myeloma is a cancer of plasma cells and is characterized by the production of abnormal immunoglobulins (Ig) or antibodies, as well as an accumulation of malignant plasma cells in the bone marrow. In some cases it can be asymptomatic, known as “smouldering” Multiple Myeloma. Although there have been several advancements in understanding how the disease develops, it is unclear as to what exactly causes it.

This report provides the current incident population for Multiple Myeloma across 18 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Ireland, Brazil, Japan, India, Saudi Arabia, South Africa, Canada, Mexico, Turkey, Argentina, Russia and Australia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Myeloma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Multiple Myeloma include:

  • Anaemia
  • Hypercalcaemia
  • Increased % of bone marrow plasma cells (BMPC %)
  • Thrombocytopenia
  • Renal failure
  • Elevated C-reactive protein

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Multiple Myeloma's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Multiple Myeloma and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Myeloma's incident population.
  • Identify sub-populations within Multiple Myeloma which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Multiple Myeloma patients.

Coverage

  • AR
  • AU
  • BR
  • CA
  • FR
  • DE
  • IN
  • IE
  • IT
  • JP
  • MX
  • RU
  • SA
  • ZA
  • ES
  • TR
  • UK
  • US

Table of Contents

Multiple Myeloma

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for Multiple Myeloma (MM)
  • Staging of Multiple Myeloma Patients
  • Features of Multiple Myeloma Patients
    • Histopathology classification of MM patients
    • Severity of Bone Lesions in MM patients
    • Type of Immunoglobulin / Monoclonal Protein Type in MM patients
  • Co-morbid Conditions Associated with Multiple Myeloma
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Durie-Salmon staging for MM
  • International Staging System for MM
  • Incidence of MM , total (000s)
  • Incidence of MM, males (000s)
  • Incidence of MM, females (000s)
  • MM patients by stage - Durie-Salmon Staging system, total (000s)
  • MM patients by stage - International Staging System, total (000s)
  • Major Hystopathological types of MM patients, total (000s)
  • Severity of bone lesions by type of MM patients, total (000s)
  • Type of Ig / Monoclonal Proteins of MM patients, total (000s)
  • Prevalence of Anaemia (<10g/dL) in MM patients, total (000s)
  • Prevalence Renal Failure at diagnosis in MM patients, total (000s)
  • Prevalence of BMPC ( ≥33 %) in MM patients, total (000s)
  • Prevalence of Elevated C- reactive protein (≥ 0.8mg/dL) in MM patients, total (000s)
  • Prevalence of Thrombocytopenia in MM patients, total (000s)
  • Prevalence of Hypercalcaemia in MM patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • USA Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • France Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • France Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Germany Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Germany Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Italy Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Italy Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Spain Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Spain Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • UK Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • UK Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Ireland Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Ireland Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Japan Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Japan Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • India Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • India Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • South Africa Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • South Africa Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Canada Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Canada Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Mexico Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Mexico Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Turkey Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Turkey Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Australia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Australia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Argentina Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Argentina Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Russia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Russia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
  • Brazil Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
  • Brazil Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
Back to Top